{"protocolSection": {"identificationModule": {"nctId": "NCT00877929", "orgStudyIdInfo": {"id": "1235.21"}, "secondaryIdInfos": [{"id": "2008-000874-19", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus", "officialTitle": "An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension."}, "statusModule": {"statusVerifiedDate": "2014-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-02"}, "primaryCompletionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-02-06", "studyFirstSubmitQcDate": "2009-04-07", "studyFirstPostDateStruct": {"date": "2009-04-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-05-13", "resultsFirstSubmitQcDate": "2011-05-13", "resultsFirstPostDateStruct": {"date": "2011-06-07", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-02-10", "lastUpdatePostDateStruct": {"date": "2014-03-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Boehringer Ingelheim, Study Chair", "oldOrganization": "Boehringer Ingelheim"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To demonstrate that the fixed dose combination of telmisartan and amlodipine is more effective in lowering blood pressure."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 706, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Telmisartan 80 / Amlodipine 10", "type": "EXPERIMENTAL", "description": "Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination", "interventionNames": ["Drug: Telmisartan 80", "Drug: Amlodipine 10"]}, {"label": "Amlodipine 10", "type": "ACTIVE_COMPARATOR", "description": "Amlodipine 5 for two weeks, then forced titration to Amlodipine 10", "interventionNames": ["Drug: Amlodipine 10"]}], "interventions": [{"type": "DRUG", "name": "Telmisartan 80", "description": "Telmisartan 80 mg", "armGroupLabels": ["Telmisartan 80 / Amlodipine 10"]}, {"type": "DRUG", "name": "Amlodipine 10", "description": "Amlodipine 5 for two weeks, then forced titration to Amlodipine 10", "armGroupLabels": ["Telmisartan 80 / Amlodipine 10"]}, {"type": "DRUG", "name": "Amlodipine 10", "description": "Amlodipine 5 for two weeks, then forced titration to Amlodipine 10", "armGroupLabels": ["Amlodipine 10"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "timeFrame": "Baseline, week 8"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "timeFrame": "Baseline, week 6"}, {"measure": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "timeFrame": "Baseline, week 4"}, {"measure": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "timeFrame": "Baseline, week 2"}, {"measure": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "timeFrame": "Baseline, week 1"}, {"measure": "Blood Pressure (BP) Control (SBP<140 mmHg, DBP<90 mmHg) at Eight Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "timeFrame": "Baseline, week 8"}, {"measure": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at Six Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "timeFrame": "Baseline, week 6"}, {"measure": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at Four Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "timeFrame": "Baseline, week 4"}, {"measure": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at Two Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "timeFrame": "Baseline, week 2"}, {"measure": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at One Week", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "timeFrame": "Baseline, week 1"}, {"measure": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Eight Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "timeFrame": "Baseline, week 8"}, {"measure": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Six Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "timeFrame": "Baseline, week 6"}, {"measure": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Four Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "timeFrame": "Baseline, week 4"}, {"measure": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Two Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "timeFrame": "Baseline, week 2"}, {"measure": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at One Week", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "timeFrame": "Baseline, week 1"}, {"measure": "Systolic Blood Pressure (SBP) Control 140 at Eight Weeks", "description": "Mean seated SBP \\< 140 mmHg", "timeFrame": "Baseline, week 8"}, {"measure": "SBP Control 140 at Six Weeks", "description": "Mean seated SBP \\< 140 mmHg", "timeFrame": "Baseline, week 6"}, {"measure": "SBP Control 140 at Four Weeks", "description": "Mean seated SBP \\< 140 mmHg", "timeFrame": "Baseline, week 4"}, {"measure": "SBP Control 140 at Two Weeks", "description": "Mean seated SBP \\< 140 mmHg", "timeFrame": "Baseline, week 2"}, {"measure": "SBP Control 140 at One Week", "description": "Mean seated SBP \\< 140 mmHg", "timeFrame": "Baseline, week 1"}, {"measure": "SBP Control 130 at Eight Weeks", "description": "Mean seated SBP \\< 130 mmHg", "timeFrame": "Baseline, week 8"}, {"measure": "SBP Control 130 at Six Weeks", "description": "Mean seated SBP \\< 130 mmHg", "timeFrame": "Baseline, week 6"}, {"measure": "SBP Control 130 at Four Weeks", "description": "Mean seated SBP \\< 130 mmHg", "timeFrame": "Baseline, week 4"}, {"measure": "SBP Control 130 at Two Weeks", "description": "Mean seated SBP \\< 130 mmHg", "timeFrame": "Baseline, week 2"}, {"measure": "SBP Control 130 at One Week", "description": "Mean seated SBP \\< 130 mmHg", "timeFrame": "Baseline, week 1"}, {"measure": "SBP Response 140 at Eight Weeks", "description": "SBP \\< 140 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 8"}, {"measure": "SBP Response 140 at Six Weeks", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 6"}, {"measure": "SBP Response 140 at Four Weeks", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 4"}, {"measure": "SBP Response 140 at Two Weeks", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 2"}, {"measure": "SBP Response 140 at One Week", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 1"}, {"measure": "SBP Response 130 at Eight Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 8"}, {"measure": "SBP Response 130 at Six Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 6"}, {"measure": "SBP Response 130 at Four Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 4"}, {"measure": "SBP Response 130 at Two Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 2"}, {"measure": "SBP Response 130 at One Week", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "timeFrame": "Baseline, week 1"}, {"measure": "DBP Response at Eight Weeks", "description": "Mean seated DBP\\<80 mmHg or a reduction of \\<=10 mmHg", "timeFrame": "Week 8"}, {"measure": "DBP Response at Six Weeks", "description": "Mean seated DBP\\<80 mmHg or a reduction of \\<=10 mmHg", "timeFrame": "week 6"}, {"measure": "DBP Response at Week Four", "description": "Mean seated DBP \\<80 mmHg or a reduction of \\>=10 mmHg", "timeFrame": "Week 4"}, {"measure": "DBP Response at Week Two", "description": "Mean seated DBP \\<80 mmHg or a reduction of \\>=10 mmHg", "timeFrame": "Week 2"}, {"measure": "DBP Response at Week One", "description": "Mean seated DBP \\<80 mmHg or a reduction of \\>=10 mmHg", "timeFrame": "Week 1"}, {"measure": "Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)", "description": "Change from baseline in UACR (measured in spot urine) after eight weeks of treatment", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Hypertension defined as a mean in-clinic seated cuff Systolic Blood Pressure \\>150 mmHg at Visit 3 (Randomisation visit)\n2. Diagnosis of Type 2 diabetes mellitus\n3. =18 years of age at the date of signing the informed consent\n4. Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)\n5. Ability to provide written informed consent\n\nExclusion criteria:\n\n1. Pre-menopausal women (last menstruation \\<=1 year prior to start of run-in period) who:\n\n   1. are not surgically sterile; and/or\n   2. are nursing or pregnant, or\n   3. are of child-bearing potential and are NOT practicing acceptable means of birth control or do NOT plan to continue practising an acceptable method throughout the study.\n\n   The only acceptable methods of birth control are:\n   * Intrauterine device (IUD);\n   * Oral contraceptives (started at least three months prior to start of run-in period)\n   * Implantable or injectable contraceptives and\n   * Estrogen patch\n2. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m.\n3. Known or suspected secondary hypertension (e.g., renal artery stenosis, phaeochromocytoma)\n4. Mean seated Systolic Blood Pressure (SBP) =180 mm Hg and/or mean seated Diastolic Blood Pressure (DBP) =110 mm Hg during any visit of the screening and placebo run-in periods\n5. Patients with Type 1 diabetes mellitus\n6. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine \\>3.0 mg/dL (or \\>265 \u00b5mol /L) or known creatinine clearance \\<30 mL/min or clinical markers of severe renal impairment\n7. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney\n8. Clinically relevant hypokalaemia or hyperkalaemia\n9. Uncorrected sodium or volume depletion\n10. Primary aldosteronism\n11. Hereditary fructose intolerance\n12. Biliary obstructive disorders (e.g., cholestatis) or hepatic insufficiency\n13. Congestive heart failure New York Heart Academy (NYHA) functional class CHF III-IV (Refer to Appendix 10.3)\n14. Contraindication to a placebo run-in period (e.g., stroke with-in the past six months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period)\n15. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator\n16. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve\n17. Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C \\>10%\n18. Patients who have previously experienced symptoms characteristic of angioedema during treatment with Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin-II receptor antagonists\n19. History of drug or alcohol dependency within six months prior to signing the informed consent form\n20. Concomitant administration of any medications known to affect blood pressure, except medications allowed by the protocol\n21. Any investigational drug therapy within one month of signing the informed consent\n22. Known hypersensitivity to any component of the study drugs (telmisartan, amlodipine, or placebo)\n23. History of non-compliance or inability to comply with prescribed medications or protocol procedures\n24. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1235.21.901 Boehringer Ingelheim Investigational Site", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "1235.21.907 Boehringer Ingelheim Investigational Site", "city": "Tustin", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "1235.21.913 Boehringer Ingelheim Investigational Site", "city": "Fort Lauderdale", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "1235.21.910 Boehringer Ingelheim Investigational Site", "city": "Hollywood", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "1235.21.903 Boehringer Ingelheim Investigational Site", "city": "Pembroke Pines", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"facility": "1235.21.905 Boehringer Ingelheim Investigational Site", "city": "Tucker", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.85455, "lon": -84.21714}}, {"facility": "1235.21.916 Boehringer Ingelheim Investigational Site", "city": "Olive Branch", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 34.96176, "lon": -89.82953}}, {"facility": "1235.21.915 Boehringer Ingelheim Investigational Site", "city": "Hickory", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.73319, "lon": -81.3412}}, {"facility": "1235.21.906 Boehringer Ingelheim Investigational Site", "city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "1235.21.902 Boehringer Ingelheim Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "1235.21.904 Boehringer Ingelheim Investigational Site", "city": "Penndel", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.15205, "lon": -74.91656}}, {"facility": "1235.21.908 Boehringer Ingelheim Investigational Site", "city": "Carrollton", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.95373, "lon": -96.89028}}, {"facility": "1235.21.909 Boehringer Ingelheim Investigational Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "1235.21.912 Boehringer Ingelheim Investigational Site", "city": "Killeen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "1235.21.911 Boehringer Ingelheim Investigational Site", "city": "Ettrick", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.24015, "lon": -77.42998}}, {"facility": "1235.21.102 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "1235.21.103 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "1235.21.107 Boehringer Ingelheim Investigational Site", "city": "Ramos Mej\u00eda", "country": "Argentina", "geoPoint": {"lat": -34.6551, "lon": -58.55318}}, {"facility": "1235.21.101 Boehringer Ingelheim Investigational Site", "city": "Santa Fe", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "1235.21.105 Boehringer Ingelheim Investigational Site", "city": "Z\u00e1rate", "country": "Argentina", "geoPoint": {"lat": -34.09814, "lon": -59.02858}}, {"facility": "1235.21.202 Boehringer Ingelheim Investigational Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "1235.21.201 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1235.21.203 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1235.21.204 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1235.21.205 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1235.21.302 Boehringer Ingelheim Investigational Site", "city": "Acapulco", "country": "Mexico", "geoPoint": {"lat": 16.86336, "lon": -99.8901}}, {"facility": "1235.21.304 Boehringer Ingelheim Investigational Site", "city": "Aguascalientes", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "1235.21.301 Boehringer Ingelheim Investigational Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "1235.21.303 Boehringer Ingelheim Investigational Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "1235.21.305 Boehringer Ingelheim Investigational Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "1235.21.306 Boehringer Ingelheim Investigational Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "1235.21.408 Boehringer Ingelheim Investigational Site", "city": "Beek en Donk", "country": "Netherlands", "geoPoint": {"lat": 51.54158, "lon": 5.62603}}, {"facility": "1235.21.406 Boehringer Ingelheim Investigational Site", "city": "Den Haag", "country": "Netherlands", "geoPoint": {"lat": 52.07667, "lon": 4.29861}}, {"facility": "1235.21.401 Boehringer Ingelheim Investigational Site", "city": "Hoogwoud", "country": "Netherlands", "geoPoint": {"lat": 52.71583, "lon": 4.93889}}, {"facility": "1235.21.405 Boehringer Ingelheim Investigational Site", "city": "Musselkanaal", "country": "Netherlands", "geoPoint": {"lat": 52.9325, "lon": 7.01528}}, {"facility": "1235.21.404 Boehringer Ingelheim Investigational Site", "city": "Nijverdal", "country": "Netherlands", "geoPoint": {"lat": 52.36, "lon": 6.46806}}, {"facility": "1235.21.403 Boehringer Ingelheim Investigational Site", "city": "Oude Pekela", "country": "Netherlands", "geoPoint": {"lat": 53.10417, "lon": 7.00972}}, {"facility": "1235.21.409 Boehringer Ingelheim Investigational Site", "city": "Roelofarensveen", "country": "Netherlands"}, {"facility": "1235.21.407 Boehringer Ingelheim Investigational Site", "city": "Voerendaal", "country": "Netherlands", "geoPoint": {"lat": 50.88327, "lon": 5.92978}}, {"facility": "1235.21.402 Boehringer Ingelheim Investigational Site", "city": "Wildervank", "country": "Netherlands", "geoPoint": {"lat": 53.08083, "lon": 6.8625}}, {"facility": "1235.21.501 Boehringer Ingelheim Investigational Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "1235.21.502 Boehringer Ingelheim Investigational Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "1235.21.503 Boehringer Ingelheim Investigational Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "1235.21.504 Boehringer Ingelheim Investigational Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "1235.21.507 Boehringer Ingelheim Investigational Site", "city": "Dunajska Streda", "country": "Slovakia", "geoPoint": {"lat": 47.99268, "lon": 17.61211}}, {"facility": "1235.21.509 Boehringer Ingelheim Investigational Site", "city": "Martin", "country": "Slovakia", "geoPoint": {"lat": 49.06651, "lon": 18.92399}}, {"facility": "1235.21.505 Boehringer Ingelheim Investigational Site", "city": "Nitra", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "1235.21.506 Boehringer Ingelheim Investigational Site", "city": "Nitra", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "1235.21.508 Boehringer Ingelheim Investigational Site", "city": "Rimavska Sobota", "country": "Slovakia", "geoPoint": {"lat": 48.38284, "lon": 20.02239}}, {"facility": "1235.21.27005 Boehringer Ingelheim Investigational Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "1235.21.27007 Boehringer Ingelheim Investigational Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "1235.21.27004 Boehringer Ingelheim Investigational Site", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "1235.21.27006 Boehringer Ingelheim Investigational Site", "city": "Johannesburg", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "1235.21.27002 Boehringer Ingelheim Investigational Site", "city": "Krugersdorp", "country": "South Africa", "geoPoint": {"lat": -26.08577, "lon": 27.77515}}, {"facility": "1235.21.27001 Boehringer Ingelheim Investigational Site", "city": "Lenasia", "country": "South Africa", "geoPoint": {"lat": -26.32052, "lon": 27.83564}}, {"facility": "1235.21.27003 Boehringer Ingelheim Investigational Site", "city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "1235.21.702 Boehringer Ingelheim Investigational Site", "city": "Castell\u00f3n", "country": "Spain"}, {"facility": "1235.21.705 Boehringer Ingelheim Investigational Site", "city": "Centelles", "country": "Spain", "geoPoint": {"lat": 41.79746, "lon": 2.21902}}, {"facility": "1235.21.703 Boehringer Ingelheim Investigational Site", "city": "Sant Adri\u00e0 del Bes\u00f3s", "country": "Spain"}, {"facility": "1235.21.704 Boehringer Ingelheim Investigational Site", "city": "Santa Coloma de Gramanet (Barcelona)", "country": "Spain"}, {"facility": "1235.21.706 Boehringer Ingelheim Investigational Site", "city": "Santa Coloma de Gramanet", "country": "Spain"}, {"facility": "1235.21.801 Boehringer Ingelheim Investigational Site", "city": "G\u00f6teborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "1235.21.803 Boehringer Ingelheim Investigational Site", "city": "Helsingborg", "country": "Sweden", "geoPoint": {"lat": 56.04673, "lon": 12.69437}}, {"facility": "1235.21.804 Boehringer Ingelheim Investigational Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "1235.21.802 Boehringer Ingelheim Investigational Site", "city": "V\u00e4ster\u00e5s", "country": "Sweden", "geoPoint": {"lat": 59.61617, "lon": 16.55276}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "FG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "352"}, {"groupId": "FG001", "numSubjects": "354"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "332"}, {"groupId": "FG001", "numSubjects": "319"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "35"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other reason (not specified)", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "BG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "352"}, {"groupId": "BG001", "value": "354"}, {"groupId": "BG002", "value": "706"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.5", "spread": "10.4"}, {"groupId": "BG001", "value": "60.5", "spread": "9.7"}, {"groupId": "BG002", "value": "60.5", "spread": "10.1"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "214"}, {"groupId": "BG001", "value": "235"}, {"groupId": "BG002", "value": "449"}]}]}, {"title": ">= 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "119"}, {"groupId": "BG002", "value": "257"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "172"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "341"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "180"}, {"groupId": "BG001", "value": "185"}, {"groupId": "BG002", "value": "365"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "American Indian/Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "12"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "70"}]}]}, {"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "84"}]}]}, {"title": "Hawaiian/Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "270"}, {"groupId": "BG001", "value": "268"}, {"groupId": "BG002", "value": "538"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "37"}]}]}, {"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "56"}]}]}, {"title": "Netherlands", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "86"}]}]}, {"title": "Argentina", "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "64"}]}]}, {"title": "Republic of Korea", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "20"}]}]}, {"title": "Sweden", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "21"}]}]}, {"title": "Slovakia", "categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "76"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "120"}, {"groupId": "BG001", "value": "121"}, {"groupId": "BG002", "value": "241"}]}]}, {"title": "South Africa", "categories": [{"measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "105"}]}]}]}, {"title": "Race class", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Non-black", "categories": [{"measurements": [{"groupId": "BG000", "value": "309"}, {"groupId": "BG001", "value": "313"}, {"groupId": "BG002", "value": "622"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "84"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "centimeter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "167.1", "spread": "10.3"}, {"groupId": "BG001", "value": "167.6", "spread": "10.9"}, {"groupId": "BG002", "value": "167.4", "spread": "10.6"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.2", "spread": "20.9"}, {"groupId": "BG001", "value": "89.5", "spread": "19.4"}, {"groupId": "BG002", "value": "89.9", "spread": "20.2"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram / square meter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.1", "spread": "6.0"}, {"groupId": "BG001", "value": "31.8", "spread": "6.1"}, {"groupId": "BG002", "value": "32.0", "spread": "6.1"}]}]}]}, {"title": "Body Mass Index Class", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 25 kg/square meter", "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "63"}]}]}, {"title": "25 to <30 kg/square meter", "categories": [{"measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "123"}, {"groupId": "BG002", "value": "237"}]}]}, {"title": ">= 30 kg/square meter", "categories": [{"measurements": [{"groupId": "BG000", "value": "206"}, {"groupId": "BG001", "value": "200"}, {"groupId": "BG002", "value": "406"}]}]}]}, {"title": "Smoking history", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Never smoked", "categories": [{"measurements": [{"groupId": "BG000", "value": "221"}, {"groupId": "BG001", "value": "222"}, {"groupId": "BG002", "value": "443"}]}]}, {"title": "Ex-smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "91"}, {"groupId": "BG001", "value": "89"}, {"groupId": "BG002", "value": "180"}]}]}, {"title": "Currently smokes", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "83"}]}]}]}, {"title": "Alcohol history", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Non drinker", "categories": [{"measurements": [{"groupId": "BG000", "value": "227"}, {"groupId": "BG001", "value": "218"}, {"groupId": "BG002", "value": "445"}]}]}, {"title": "Drinks - no interference", "categories": [{"measurements": [{"groupId": "BG000", "value": "125"}, {"groupId": "BG001", "value": "136"}, {"groupId": "BG002", "value": "261"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "populationDescription": "Treated Set includes all randomized participants who took at least one dose of treatment", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "320"}, {"groupId": "OG001", "value": "311"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-29.0", "spread": "0.66"}, {"groupId": "OG001", "value": "-22.9", "spread": "0.67"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.1", "ciPctValue": "95", "ciLowerLimit": "-7.9", "ciUpperLimit": "-4.2"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "326"}, {"groupId": "OG001", "value": "317"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-29.7", "spread": "0.62"}, {"groupId": "OG001", "value": "-22.6", "spread": "0.63"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.1", "ciPctValue": "95", "ciLowerLimit": "-8.9", "ciUpperLimit": "-5.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-27.7", "spread": "0.62"}, {"groupId": "OG001", "value": "-21.1", "spread": "0.62"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.6", "ciPctValue": "95", "ciLowerLimit": "-8.3", "ciUpperLimit": "-4.9"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg"}, {"id": "OG001", "title": "Amlodipine 5 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "333"}, {"groupId": "OG001", "value": "332"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.4", "spread": "0.65"}, {"groupId": "OG001", "value": "-16.4", "spread": "0.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.1", "ciPctValue": "95", "ciLowerLimit": "-7.9", "ciUpperLimit": "-4.3"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1", "description": "Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg"}, {"id": "OG001", "title": "Amlodipine 5 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-17.5", "spread": "0.61"}, {"groupId": "OG001", "value": "-12.6", "spread": "0.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Included effects of treatment, week and treatment-by-week interaction with covariate of baseline blood pressure and baseline-week interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.9", "ciPctValue": "95", "ciLowerLimit": "-6.6", "ciUpperLimit": "-3.2"}]}, {"type": "SECONDARY", "title": "Blood Pressure (BP) Control (SBP<140 mmHg, DBP<90 mmHg) at Eight Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "populationDescription": "Treated set using last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "329"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "177"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at Six Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "245"}, {"groupId": "OG001", "value": "168"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at Four Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "235"}, {"groupId": "OG001", "value": "155"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at Two Weeks", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "341"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "103"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<140 mmHg, DBP<90 mmHg) at One Week", "description": "Mean seated SBP\\<140 mmHg and mean seated DBP\\<90 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "72"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Eight Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "329"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "59"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Six Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "60"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Four Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "38"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at Two Weeks", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "341"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "23"}]}]}]}, {"type": "SECONDARY", "title": "BP Control (SBP<130 mmHg, DBP<80 mmHg) at One Week", "description": "Mean seated SBP\\<130 mmHg and mean seated DBP\\<80 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure (SBP) Control 140 at Eight Weeks", "description": "Mean seated SBP \\< 140 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "329"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "243"}, {"groupId": "OG001", "value": "187"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 140 at Six Weeks", "description": "Mean seated SBP \\< 140 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "251"}, {"groupId": "OG001", "value": "177"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 140 at Four Weeks", "description": "Mean seated SBP \\< 140 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "243"}, {"groupId": "OG001", "value": "163"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 140 at Two Weeks", "description": "Mean seated SBP \\< 140 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "341"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "112"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 140 at One Week", "description": "Mean seated SBP \\< 140 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "81"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 130 at Eight Weeks", "description": "Mean seated SBP \\< 130 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "329"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "89"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 130 at Six Weeks", "description": "Mean seated SBP \\< 130 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "81"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 130 at Four Weeks", "description": "Mean seated SBP \\< 130 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "70"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 130 at Two Weeks", "description": "Mean seated SBP \\< 130 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "341"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "42"}]}]}]}, {"type": "SECONDARY", "title": "SBP Control 130 at One Week", "description": "Mean seated SBP \\< 130 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "26"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 140 at Eight Weeks", "description": "SBP \\< 140 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "329"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "309"}, {"groupId": "OG001", "value": "288"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 140 at Six Weeks", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "286"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 140 at Four Weeks", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "309"}, {"groupId": "OG001", "value": "274"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 140 at Two Weeks", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "341"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "297"}, {"groupId": "OG001", "value": "246"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 140 at One Week", "description": "SBP \\<140 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "253"}, {"groupId": "OG001", "value": "201"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 130 at Eight Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "329"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "309"}, {"groupId": "OG001", "value": "288"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 130 at Six Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "286"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 130 at Four Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "309"}, {"groupId": "OG001", "value": "274"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 130 at Two Weeks", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "341"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "297"}, {"groupId": "OG001", "value": "246"}]}]}]}, {"type": "SECONDARY", "title": "SBP Response 130 at One Week", "description": "SBP \\<130 mmHg or a reduction \\>=10 mmHg", "populationDescription": "Treated set using LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "253"}, {"groupId": "OG001", "value": "199"}]}]}]}, {"type": "SECONDARY", "title": "DBP Response at Eight Weeks", "description": "Mean seated DBP\\<80 mmHg or a reduction of \\<=10 mmHg", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "329"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "253"}, {"groupId": "OG001", "value": "214"}]}]}]}, {"type": "SECONDARY", "title": "DBP Response at Six Weeks", "description": "Mean seated DBP\\<80 mmHg or a reduction of \\<=10 mmHg", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 6", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "214"}]}]}]}, {"type": "SECONDARY", "title": "DBP Response at Week Four", "description": "Mean seated DBP \\<80 mmHg or a reduction of \\>=10 mmHg", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "190"}]}]}]}, {"type": "SECONDARY", "title": "DBP Response at Week Two", "description": "Mean seated DBP \\<80 mmHg or a reduction of \\>=10 mmHg", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 2", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "341"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "166"}]}]}]}, {"type": "SECONDARY", "title": "DBP Response at Week One", "description": "Mean seated DBP \\<80 mmHg or a reduction of \\>=10 mmHg", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 1", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 5 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 5 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "165"}, {"groupId": "OG001", "value": "113"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)", "description": "Change from baseline in UACR (measured in spot urine) after eight weeks of treatment", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "333"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.36", "spread": "0.79"}, {"groupId": "OG001", "value": "0.04", "spread": "0.92"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Telmisartan 80 mg + Amlodipine 10 mg", "description": "Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 352, "otherNumAffected": 62, "otherNumAtRisk": 352}, {"id": "EG001", "title": "Amlodipine 10 mg", "description": "Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.", "seriousNumAffected": 4, "seriousNumAtRisk": 354, "otherNumAffected": 71, "otherNumAtRisk": 354}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Ulcer", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 354}]}, {"term": "Hepatitis alcoholic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 354}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 354}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Major depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 354}]}, {"term": "Arteriosclerosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 354}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (13.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 62, "numAtRisk": 352}, {"groupId": "EG001", "numAffected": 71, "numAtRisk": 354}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000077333", "term": "Telmisartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M1770", "name": "Telmisartan", "asFound": "Fixed dose", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}